You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》招銀國際一舉升復宏漢霖(02696.HK)目標價至61.98元 料創新藥研發有龐大潛力
阿思達克 06-25 11:13
招銀國際發表研究報告指,復宏漢霖(02696.HK)有能力從一家正在盈利的生物類似藥公司,發展成為生物製劑領域的領先企業,包括HLX43、HLX22、斯魯利單抗(Serplulimab)等多款正在研發的創新藥臨床數據均表現良好,相信發展潛力龐大, 因此目標價從20.33元一舉上調至61.98元,維持「買入」評級。 招銀國際認為,復宏漢霖正積極通過與藥企合作,拓展全球生物類似藥業務,旗下「漢曲優」(曲妥珠單抗)及斯魯利單抗商業化表現強勁,而HLX14和HLX11的上市許可申請目前正獲FDA審查當中,相信可開招海外收入來源。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account